StockNews.AISignal intelligence
Prothena Corporation plc · NASDAQ · Healthcare
Browse public PRTA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Prothena's Phase 3 trial for birtamimab failed primary endpoint. Company will discontinue development of birtamimab following disappointing results. PRTA stock fell 26.80% post-announcement; plans for cost reductions underway. Future data readouts for Alzheimer's drug PRX012 are anticipated within 18 months. Workforce reductions and business evaluations are planned to benefit shareholders.
View signal analysisProthena's RSI is at 21.9, indicating oversold conditions. Stock price has fallen 31% recently; currently at $7.10. Clinical trial data expected in 2025 could influence future performance. Weaker quarterly results posted on May 8 raises investor concerns. Momentum score of 5.29 shows potential for recovery despite current challenges.
View signal analysis- Prothena (PRTA) reported a wider loss per share due to higher expenses and lower revenues. - Total revenues in Q1 were $0.05 million, missing estimates and declining from the previous year. - Pipeline updates include ongoing studies for Alzheimer's and Parkinson's disease treatments. - Share price of PRTA has fallen 36.6% year to date compared to the industry. Price Impact Rating: Bearish Impact Horizon Rating: Long-term Type: Research Analysis
View signal analysis- Prothena reported a quarterly loss of $1.34 per share, missing estimates and a year ago. - Company posted revenues of $0.05 million, missing estimates by 98.67%. - Prothena shares have lost 35.2% YTD against S&P 500's gain of 8.8%. - Management's commentary and future earnings will determine Prothena's stock movement. - Zacks Rank holds Prothena at #3 (Hold) with a mixed estimate revisions trend. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Research Analysis
View signal analysis